ライフサイエンスコーパス: transcription product

1 f IAP transcripts, Gag proteins, and reverse transcription products.

2 ntry, before the generation of viral reverse transcription products.

3 ability of MLV particles to generate reverse transcription products.

4 prising approximately 80% of the total viral transcription products.

5 mate size expected for a full-length reverse transcription product and with plus-strand strong-stop D

6 rastically decreased wild-type HIV-1 reverse transcription products and infectivity.

7 decreased amounts of early and late reverse transcription products and integrated virus relative to

8 ee-way junction structure diminished reverse transcription products and led to reduced viral infectiv

9 xosomes reduce accumulation of HIV-1 reverse transcription products and steady-state levels of HIV-1

10 ing strategy to characterize nascent reverse transcription products and their precise 3'-termini in H

11 , results in reduced accumulation of reverse transcription products, and is dominant in heterokaryons

12 tilize an unspliced version of their primary transcription product as an RNA template for synthesis o

13 em, Transchip, was developed for analysis of transcription products at their genomic origins.

14 is to investigate the length distribution of transcription products at various times following initia

15 The standard is added to the reverse transcription product before PCR.

16 oncoding RNAs (lncRNAs) are not only passive transcription products, but also major regulators of gen

17 and MDDCs revealed similar levels of reverse transcription products, but increased nuclear import in

18 es by preventing the accumulation of reverse transcription products, but the underlying mechanism rem

19 evealed that the generation of early reverse transcription products coincides with the timing of unco

20 integration, indicating that a viral reverse transcription product comprises the HIV-1 pathogen-assoc

21 ll mutants tested produced levels of reverse transcription products either similar to or only somewha

22 Finally, HIV-1 reverse transcription products escaping rhesus TRIM5alpha restri

23 the normal generation of HIV-1 late reverse transcription products, even though HIV-1 infection and

24 llowing a blood meal, and those accumulating transcription products exclusively or preferentially in

25 after virion entry and prevent viral reverse transcription products from accumulating.

26 how a decreased tendency to produce aberrant transcription products from DNA templates having protrud

27 The quantitative measurement of transcription products from homologous alleles at a dipl

28 e was determined by real-time PCR on reverse transcription products from RNA isolated from human corn

29 to other cytosolic sensors of viral reverse transcription products in newly infected cells.

30 Analysis of reverse transcription products in OMK cells revealed that the ge

31 e conserved exonic IES determine alternative transcription products in the developing macronucleus; s

32 , prior to the accumulation of viral reverse transcription products in the target cell.

33 bition, prevents the accumulation of reverse transcription products in the target cell.

34 aggregates promote synthesis of long reverse transcription products in vitro by concentrating nucleic

35 Other classes of reverse transcription products, including some that resulted fro

36 te the synthesis of RNA polymerase (Pol) III transcription products, including tRNAs and 5S rRNAs, wa

37 tive real-time PCR analysis of early reverse transcription products indicated that HIV-1 reverse tran

38 We detected truncated transcription products indicating partial transcription

39 iant was impaired in generating late reverse transcription products, indicating that replication was

40 , and mediate the integration of the reverse-transcription product into the genome of the host cell.

41 The retroviral primary transcription product is a multifunctional RNA that is u

42 multiple ways and that inhibition of reverse transcription products is not necessary for TRIM5-mediat

43 at synthesis of long double-stranded reverse transcription products is required to trigger efficient

44 eatment alleviated the decrease in mtDNA and transcription product levels induced by mitochondrial AP

45 tantially reduced, neither the amount of HBV transcription products nor the core polypeptide was dete

46 lding a short, truncated L mRNA as the major transcription product of the L gene.

47 s oxyR homolog and provide evidence that the transcription product of this gene binds to the B. abort

48 For this study, we examined reverse transcription products of human immunodeficiency virus (

49 that, like p53, p73alpha and the alternative transcription product p73beta also bind MDM2.

50 antitative real-time PCR analysis of reverse transcription products revealed that the mutant RTs were

51 Detailed analyses of the reverse transcription products synthesized within nucleocapsids

52 e, and cell death through an undefined CIITA transcription product that may serve as a new antiviral

53 iency virus type 1 (HIV-1), allowing reverse transcription products to accumulate even though viral i

54 ication, including synthesis of late reverse transcription products, two-long terminal repeat circles

55 ve methods that monitor formation of reverse transcription products, two-LTR circles and integrated p

56 microring resonators to detect cDNA reverse transcription products via a subsequent enzymatic signal

57 Although most of the primary transcription products were multigenomic in length, some

58 However, reverse transcription products were substantially increased in t

59 indicate that faithful, full-length reverse transcription products were underrepresented in the abse

60 ction and quantitative PCR for HIV-1 reverse transcription products, whereas treatment of the target

61 tive real-time PCR analysis of early reverse transcription products, with initiation at the HIV-1 PBS

62 thesis.IMPORTANCE The fates of HIV-1 reverse transcription products within infected cells are not wel

63 r viral DNA as well as intracellular reverse transcription products, without affecting HBV RNAs or cc